Scientific opinion on the safety of monacolins in red yeast rice
暂无分享,去创建一个
P. Galtier | R. Andrade | M. Younes | P. Mosesso | P. Aggett | M. Filipič | P. Restani | F. Aguilar | R. Crebelli | D. Gott | J. Leblanc | U. Gundert-Remy | C. Lambré | I. Lillegaard | A. Mortensen | P. Moldéus | I. Waalkens-Berendsen | C. Smeraldi | M. Wright | B. Dusemund | M. Frutos | G. Kuhnle | A. Oskarsson | I. Stanković | R. Woutersen | F. Pizzo | C. Fortes | I. T. Lillegaard | R. Andrade | Riccardo Crebelli
[1] Peijie Chen,et al. A case of erectile dysfunction induced by red yeast rice in lipid‐lowering therapy , 2018, Phytotherapy research : PTR.
[2] I. Khan,et al. Variability in strength of red yeast rice supplements purchased from mainstream retailers , 2017, European journal of preventive cardiology.
[3] E. Raschi,et al. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system , 2017, British journal of clinical pharmacology.
[4] M. Perri,et al. When Nutraceuticals Reinforce Drugs Side Effects: A Case Report. , 2016, Current drug safety.
[5] M. Jean-Pastor,et al. Atteintes musculaires et levure de riz rouge : analyse des données de la base nationale de pharmacovigilance et revue de la littérature ☆ , 2016 .
[6] A. Hahn,et al. Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention. , 2016, Nutrition research.
[7] B. Venhuis,et al. Pharmacologically effective red yeast rice preparations marketed as dietary supplements illustrated by a case report. , 2016, Drug testing and analysis.
[8] C. Guy,et al. [Red yeast-rice-induced muscular injuries: Analysis of French pharmacovigilance database and literature review]. , 2016, Therapie.
[9] Fusheng Chen,et al. Edible Filamentous Fungi from the Species Monascus: Early Traditional Fermentations, Modern Molecular Biology, and Future Genomics , 2015 .
[10] V. Gerdes,et al. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. , 2015, Atherosclerosis.
[11] Frances M. Burke. Red Yeast Rice for the Treatment of Dyslipidemia , 2015, Current Atherosclerosis Reports.
[12] J. Neher,et al. Clinical inquiry: is red-yeast rice a safe and effective alternative to statins? , 2015, The Journal of family practice.
[13] H. Monteiro,et al. Treatment of Dyslipidemia with Statins and Physical Exercises: Recent Findings of Skeletal Muscle Responses. , 2015, Arquivos brasileiros de cardiologia.
[14] I. Khan,et al. Chemical profiling and quantification of monacolins and citrinin in red yeast rice commercial raw materials and dietary supplements using liquid chromatography-accurate QToF mass spectrometry: Chemometrics application. , 2014, Journal of pharmaceutical and biomedical analysis.
[15] Cesare R Sirtori,et al. The pharmacology of statins. , 2014, Pharmacological research.
[16] Long Jiang,et al. A Meta-Analysis of Red Yeast Rice: An Effective and Relatively Safe Alternative Approach for Dyslipidemia , 2014, PloS one.
[17] D. Shih,et al. Incidence of citrinin in red yeast rice and various commercial Monascus products in Taiwan from 2009 to 2012 , 2014 .
[18] D. Popovich,et al. Red azaphilone pigments extracted from red yeast rice induces cellular senescence and reduces viability in HepG2 cells , 2013 .
[19] A. S. Vidyarthi,et al. A review on lovastatin and its production , 2013 .
[20] J. DiNicolantonio,et al. Red yeast rice for dysipidemia. , 2013, Missouri medicine.
[21] B. Nigović,et al. Simultaneous determination of lovastatin and citrinin in red yeast rice supplements by micellar electrokinetic capillary chromatography. , 2013, Food chemistry.
[22] R. Beckett,et al. Peripheral neuropathy induced by red yeast rice in a patient with a known small bowel gastrointestinal tumour , 2013, BMJ Case Reports.
[23] Jyh-Chin Yang,et al. Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. , 2013, International journal of pharmaceutics.
[24] Efsa Panel on Dietetic Products. Scientific Opinion on the substantiation of a health claim related to monacolin K in SYLVAN BIO red yeast rice and maintenance of normal blood LDL-cholesterol concentrations pursuant to Article 13(5) of Regulation (EC) No 1924/2006 , 2013 .
[25] Ana Mornar,et al. Development of a rapid LC/DAD/FLD/MS(n) method for the simultaneous determination of monacolins and citrinin in red fermented rice products. , 2013, Journal of agricultural and food chemistry.
[26] P. Patakova. Monascus secondary metabolites: production and biological activity , 2013, Journal of Industrial Microbiology & Biotechnology.
[27] Jyh-Chin Yang,et al. Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin , 2012, Evidence-based complementary and alternative medicine : eCAM.
[28] T. Weir,et al. Fermented foods: patented approaches and formulations for nutritional supplementation and health promotion. , 2012, Recent patents on food, nutrition & agriculture.
[29] S. Saeger,et al. Scientific Opinion on the risks for public and animal health related to the presence of citrinin in food and feed , 2012 .
[30] Efsa Panel on Dietetic Products. Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 , 2011 .
[31] David J. Becker,et al. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! , 2010, Archives of internal medicine.
[32] T. Hagve,et al. HypoCol (red yeast rice) lowers plasma cholesterol – a randomized placebo controlled study , 2010, Scandinavian cardiovascular journal : SCJ.
[33] N. Ayoub,et al. Azaphilones: a class of fungal metabolites with diverse biological activities , 2010, Phytochemistry Reviews.
[34] David J. Becker,et al. Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients , 2009, Annals of Internal Medicine.
[35] M. Pompili,et al. Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all. , 2009, Journal of hepatology.
[36] Josef Schlatter,et al. Transparency in Risk Assessment - Scientific Aspects Guidance of the Scientific Committee on Transparency in the Scientific Aspects of Risk Assessments carried out by EFSA. Part 2: General , 2009 .
[37] J. Kocher,et al. Symptomatic hepatitis associated with the use of herbal red yeast rice. , 2008, Annals of internal medicine.
[38] A. Vannacci,et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. , 2008, British journal of clinical pharmacology.
[39] C. Ballantyne,et al. A case report of myopathy from consumption of red yeast rice. , 2008, Journal of clinical lipidology.
[40] Nan-Wei Su,et al. Biologically active components and nutraceuticals in the Monascus-fermented rice: a review , 2008, Applied Microbiology and Biotechnology.
[41] C. Liu,et al. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[42] P. Mueller. Symptomatic myopathy due to red yeast rice. , 2006, Annals of internal medicine.
[43] T. Mongini,et al. CHINESE RED RICE DEPLETES MUSCLE COENZYME Q10 AND MAINTAINS MUSCLE DAMAGE AFTER DISCONTINUATION OF STATIN TREATMENT , 2006, Journal of the American Geriatrics Society.
[44] G. Eisenbrand. Toxicological evaluation of red mould rice. , 2006, Molecular nutrition & food research.
[45] N. Seeram,et al. Plasma clearance of lovastatin versus chinese red yeast rice in healthy volunteers. , 2005, Journal of alternative and complementary medicine.
[46] Tsai-Chung Li,et al. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. , 2005, European journal of endocrinology.
[47] Fusheng Chen,et al. Study on red fermented rice with high concentration of monacolin K and low concentration of citrinin. , 2005, International journal of food microbiology.
[48] Michael Schachter,et al. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update , 2005, Fundamental & clinical pharmacology.
[49] T. Pan,et al. Modified mutation method for screening low citrinin-producing strains of Monascus purpureus on rice culture. , 2004, Journal of agricultural and food chemistry.
[50] Zheng-Tao Wang,et al. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. , 2004, Journal of pharmaceutical and biomedical analysis.
[51] J. MacDonald,et al. The Toxicology of HMG—CoA Reductase Inhibitors: Prediction of Human Risk , 2004, Toxicologic pathology.
[52] K. Olive,et al. Chinese Red Rice-induced Myopathy , 2003, Southern medical journal.
[53] G. Prasad,et al. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. , 2002, Transplantation.
[54] C. Stancu,et al. Statins: mechanism of action and effects , 2001, Journal of cellular and molecular medicine.
[55] A. Gotto,et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. , 2001, The American journal of cardiology.
[56] D. Zhang,et al. Constituents of red yeast rice, a traditional Chinese food and medicine. , 2000, Journal of agricultural and food chemistry.
[57] P. Elsner,et al. Anaphylaxis due to Monascus purpureus‐fermented rice (red yeast rice) , 1999, Allergy. European Journal of Allergy and Clinical Immunology.
[58] M. Sabater-Vilar,et al. Mutagenicity of commercial Monascus fermentation products and the role of citrinin contamination. , 1999, Mutation research.
[59] R. Elashoff,et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. , 1999, The American journal of clinical nutrition.
[60] V. Havlíček,et al. Biological activities of oligoketide pigments of Monascus purpureus. , 1999, Food additives and contaminants.
[61] P. Neuvonen,et al. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid , 1998, Clinical pharmacology and therapeutics.
[62] H. Lennernäs,et al. Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.
[63] M Vuelta,et al. [Food-drug interactions]. , 1997, Enfermeria intensiva.
[64] W. O’Neill,et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. , 1994, The New England journal of medicine.
[65] C. Furberg,et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.
[66] D. Hunninghake,et al. Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[67] A. Y. Lu,et al. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.
[68] A. Serajuddin,et al. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. , 1991, Journal of pharmaceutical sciences.
[69] C. Shear,et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. , 1991, The American journal of medicine.
[70] W. F. Hoffman,et al. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[71] D. E. Duggan,et al. Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[72] I. Chen,et al. The physiological disposition of lovastatin. , 1989, Drug Metabolism And Disposition.
[73] J. L. Smith,et al. Metabolism of lovastatin by rat and human liver microsomes in vitro. , 1988, Drug metabolism and disposition: the biological fate of chemicals.
[74] D. Hawksworth,et al. A new taxonomy for Monascus species based on cultural and microscopical characters , 1983 .
[75] R Monaghan,et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[76] W. Fishbein,et al. Purification and Properties of an Enzyme in Human Blood and Rat Liver Microsomes Catalyzing the Formation and Hydrolysis of γ-Lactones II. METAL ION EFFECTS, KINETICS, AND EQUILIBRIA , 1966 .
[77] W. Fishbein,et al. Purification and properties of an enzyme in human blood and rat liver microsomes catalyzing the formation and hydrolysis of gamma-lactones. II. Metal ion effects, kinetics, and equilibra. , 1966, The Journal of biological chemistry.